Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021
Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood. Tests and procedures used to diagnose neuroblastoma include: physical exam, urine and blood tests, imaging tests, removing a sample of tissue for testing, and removing a sample of bone marrow for testing. Treatment options include: surgery, chemotherapy, radiation therapy, stem cell transplant, and immunotherapy. Newer treatments include newer form of radiation therapy that may help control high-risk neuroblastoma. The treatment uses a radioactive form of the chemical metaiodobenzylguanidine (MIBG). When injected in to the bloodstream, the MIBG travels to the neuroblastoma cells and releases the radiation. MIBG therapy is sometimes combined with chemotherapy or stem cell transplant.
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
1.3.3 Years Considered in the Study
1.4 Limitations
1.5 Market Stakeholders
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Executive Summary
4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Segmentation
5.3 Market Evolution
5.4 Market Dynamics
5.4.1 Key Market Drivers
5.4.2 Key Market Restraints
5.4.3 Key Market Opportunities
5.4.4 Key Market Challenges
6 Industry Insights
6.1 Introduction
6.2 Epidemiology Coverage
6.3 Pricing and Reimbursement Analysis
6.4 Treatment Protocols
6.5 Key Products Expected to Be Launched in the Market
6.6 Ongoing Clinical Trials
7 Neuroblastoma Market Diagnostics
7.1 Introduction
7.2 Metaiodobenzylguanidine (MIBG) Scan
7.3 Imaging of the Primary Tumor Mass
7.4 Urine Catecholamine Metabolites
7.5 Biopsy
8 Neuroblastoma Market, By Staging
8.1 Introduction
8.2 Stage I
8.3 Stage IIA
8.4 Stage IIB
8.5 Stage III
8.6 Stage IV
8.7 Stage IVS (Special Category)
9 Neuroblastoma Market, By Treatment
9.1 Introduction
9.2 Surgery
9.3 Chemotherapy
9.4 Radiation Therapy
9.5 Stem Cell Transplant
9.6 Immunotherapy
10 Neuroblastoma Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Rest of the World (RoW)
11 Competitive Landscape
11.1 Introduction
11.2 Market Share Analysis, By Key Players
11.3 Competitive Scenario
11.4 Recent Developments
11.4.1 New Products Launches and Product Enhancements
11.4.2 Agreement/Partnership/Collaboration
11.4.3 Mergers and Acquisitions
11.4.4 Geographic Expansions
11.4.5 Other Developments
12 Company Profiles*
13 Appendix
13.1 Insights From Industry Experts
13.2 Discussion Guide
13.3 Introducing RT: Real Time Market Intelligence
13.4 Available Customizations
13.5 Related Reports
*Will Cover Ten Leading Companies in the Market.
Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.
Growth opportunities and latent adjacency in Neuroblastoma Cancer Market